$119.97
0.77% yesterday
NYSE, Nov 04, 10:00 pm CET
ISIN
US23918K1088
Symbol
DVA

DaVita HealthCare Partners Stock price

$119.97
-8.17 6.38% 1M
-21.60 15.26% 6M
-29.58 19.78% YTD
-24.97 17.23% 1Y
+49.59 70.46% 3Y
+23.93 24.92% 5Y
+42.52 54.90% 10Y
+94.16 364.82% 20Y
NYSE, Closing price Tue, Nov 04 2025
+0.92 0.77%

New AI Insights on DaVita HealthCare Partners Insights AI Insights on DaVita HealthCare Partners

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$8.5b
Enterprise Value
$18.0b
Net debt
$9.5b
Cash
$739.4m
Shares outstanding
74.2m
Valuation (TTM | estimate)
P/E
11.1 | 10.9
P/S
0.6 | 0.6
EV/Sales
1.4 | 1.3
EV/FCF
14.0
P/B
negative
Financial Health
Equity Ratio
0.7%
Return on Equity
773.1%
ROCE
13.6%
ROIC
10.4%
Debt/Equity
-27.8
Financials (TTM | estimate)
Revenue
$13.2b | $13.6b
EBITDA
$2.7b | $2.8b
EBIT
$2.0b | $2.1b
Net Income
$836.3m | $814.3m
Free Cash Flow
$1.3b
Growth (TTM | estimate)
Revenue
5.1% | 6.0%
EBITDA
3.8% | 5.0%
EBIT
7.2% | 6.7%
Net Income
-2.7% | -13.0%
Free Cash Flow
1.5%
Margin (TTM | estimate)
Gross
32.5%
EBITDA
20.4% | 20.7%
EBIT
15.0%
Net
6.4% | 6.0%
Free Cash Flow
9.8%
More
EPS
$10.8
FCF per Share
$17.4
Short interest
18.8%
Employees
76k
Rev per Employee
$170.0k
Show more

Is DaVita HealthCare Partners a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

DaVita HealthCare Partners Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a DaVita HealthCare Partners forecast:

1x Buy
6%
10x Hold
59%
6x Sell
35%

Analyst Opinions

17 Analysts have issued a DaVita HealthCare Partners forecast:

Buy
6%
Hold
59%
Sell
35%

Financial data from DaVita HealthCare Partners

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
13,161 13,161
5% 5%
100%
- Direct Costs 8,878 8,878
5% 5%
67%
4,283 4,283
5% 5%
33%
- Selling and Administrative Expenses 1,595 1,595
6% 6%
12%
- Research and Development Expense - -
-
-
2,688 2,688
4% 4%
20%
- Depreciation and Amortization 712 712
5% 5%
5%
EBIT (Operating Income) EBIT 1,976 1,976
7% 7%
15%
Net Profit 836 836
3% 3%
6%

In millions USD.

Don't miss a Thing! We will send you all news about DaVita HealthCare Partners directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DaVita HealthCare Partners Stock News

Neutral
PRNewsWire
about 19 hours ago
Six  new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Hous...
Positive
The Motley Fool
3 days ago
DaVita is cheap considering its long-term growth potential. Buy Kraft Heinz for its high yield, stay for the restructuring that could unlock the food company's underlying value.
Neutral
Seeking Alpha
6 days ago
DaVita Inc. ( DVA ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Nic Eliason - Group Vice President of Investor Relations Javier Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Conference Call Participants Kevin Fischbeck - BofA Securities, Research Division Andrew Mok - Barclays Bank PLC, Research Division Albert Rice - UBS Investment Bank, Resea...
More DaVita HealthCare Partners News

Company Profile

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Head office United States
CEO Javier Rodriguez
Employees 76,000
Founded 1994
Website www.davita.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today